Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case‐Based Evidence
Obesity · 2026-09 · 34 (S2) · 64-69
DOI: 10.1002/oby.70256 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Obesity, online erschienen am 03.07.2026. Verfasst von Janice Bidesie und 1 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Psychology, Helmholtz Institute, Utrecht University, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Thiamine Deficiency, Wernicke Encephalopathy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Glucagon‐like peptide‐1 receptor agonists are increasingly prescribed for obesity. Although generally considered safe, marked appetite suppression and persistent gastrointestinal adverse effects may increase the risk of nutritional deficiencies. Wernicke's encephalopathy (WE), caused by thiamine deficiency, is a rare but potentially fatal neurological disorder that may result in irreversible cognitive impairment if not promptly recognized and treated. Recently, cases of WE associated with semaglutide use have been reported. This study aimed to systematically review published case reports of WE occurring after semaglutide treatment for obesity from an endocrinological drug safety perspective.
Methods
A systematic literature search was conducted in PubMed, Embase, CINAHL, and Scopus according to PRISMA guidelines. Case reports were included when semaglutide was prescribed for obesity and the presentation was consistent with WE.
Results
Six cases were identified. All patients experienced prolonged gastrointestinal symptoms and substantial weight loss before neurological deterioration. Common manifestations included altered mental status and oculomotor abnormalities. Outcomes were poor in several cases, including progression to Korsakoff syndrome or death.
Conclusions
Clinicians should remain vigilant for thiamine deficiency in patients with persistent gastrointestinal intolerance or rapid weight loss during GLP‐1 treatment, as early parenteral thiamine administration is essential to prevent irreversible neurological sequelae.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Psychology, Helmholtz Institute, Utrecht University, Utrecht, the Netherlands.
- Slingedael Center of Expertise for Korsakoff Syndrome, Lelie Care Group, Rotterdam, the Netherlands.
- Long Term Intensive Treatment, Parnassia Psychiatric Institute, The Hague, the Netherlands.
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands.
ORCID-Profile: Erik Oudman
Zitieren
APA
Bidesie, J., & Oudman, E. (2026). Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case‐Based Evidence. Obesity, 34(S2), 64-69. https://doi.org/10.1002/oby.70256
Vancouver
Bidesie J, Oudman E. Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case‐Based Evidence. Obesity. 2026;34(S2):64-69. doi:10.1002/oby.70256
BibTeX
@article{Bidesie2026,
author = {Bidesie, Janice and Oudman, Erik},
title = {Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case‐Based Evidence},
journal = {Obesity},
year = {2026},
volume = {34},
number = {S2},
pages = {64--69},
doi = {10.1002/oby.70256}
}
EUVIMED